Aethlon Medical, Inc. (AEMD): Marketing Mix Analysis [Dec-2025 Updated]

You're looking at Aethlon Medical, Inc. (AEMD), and for a company with $0.00 in product revenue for the 2025 fiscal year, their marketing mix is defintely a high-stakes clinical and capital strategy, not a typical sales pitch. The core 'Product' is the Hemopurifier, a blood filtration device being tested in critical oncology trials in Australia, but the real 'Price' story is in their balance sheet: they cut Q2 2026 operating expenses by 48% to about $1.5 million while raising roughly $4.5 million in gross proceeds from a September 2025 public offering to fund those trials. This is a pure R&D play, so you need to look past typical sales channels and focus on clinical milestones and a cash balance of approximately $5.8 million to understand their true market position.

Aethlon Medical, Inc. (AEMD) - Marketing Mix: Product

The core product is the Aethlon Hemopurifier, an investigational, extracorporeal (outside the body) medical device. It is a blood filtration system designed to remove harmful components from a patient's circulation, and its development is currently focused on two critical, high-unmet-need areas: advanced cancer and life-threatening infectious diseases.

The product's value proposition is simple: by clearing the blood of specific pathogenic targets, it aims to restore the body's natural immune function. This device holds a U.S. Food and Drug Administration (FDA) Breakthrough Device Designation for both its primary indications, which should defintely accelerate its regulatory pathway.

Aethlon Hemopurifier: An Investigational, Extracorporeal Device

The Hemopurifier is a single-use cartridge used in conjunction with a standard blood pump, similar to a dialysis or plasmapheresis machine. It functions as a therapeutic blood filter, and because it is an investigational device, all current use is confined to clinical trials and research. For the fiscal year ended March 31, 2025, Aethlon Medical's consolidated operating expenses were approximately $9.3 million, reflecting the significant investment required to advance this clinical-stage product.

The product's design is focused on safety and feasibility in its current trials. In the second quarter of fiscal year 2026 (ended September 30, 2025), consolidated operating expenses were reduced to approximately $1.5 million, a 48% decrease from the prior year, demonstrating a disciplined approach to capital allocation while advancing the product.

Core Technology Targets Removal of Tumor-Derived Extracellular Vesicles (EVs) and Enveloped Viruses

The device's mechanism of action is its key differentiator. It employs a proprietary affinity resin containing the plant lectin Galanthus nivalis agglutinin (GNA), which selectively binds to mannose-rich surfaces. This GNA resin is designed to capture two main pathogenic targets:

• Tumor-Derived Extracellular Vesicles (EVs): Nanoparticles released by tumor cells that suppress the immune system and promote metastasis.
• Enveloped Viruses: Viruses such as SARS-CoV-2, Ebola, and HIV, which have a lipid envelope with mannose-rich proteins.

Preclinical data supports the product's efficacy in removing these targets. An ex vivo study, published in May 2025, demonstrated the Hemopurifier's ability to remove 98.5% of platelet-derived extracellular vesicles (PD-EVs) from human plasma during a simulated 4-hour treatment. This precise, measurable performance is crucial for a medical device aiming for regulatory approval.

Primary Indications: Advanced/Metastatic Cancer and Life-Threatening Infectious Diseases

The FDA's Breakthrough Device Designation highlights the Hemopurifier's potential in two severe, life-threatening conditions where current treatments fall short.

Active Clinical Focus on Oncology Trials in Australia for Solid Tumors Non-Responsive to PD-1 Agents

The most tangible near-term product development is the ongoing safety, feasibility, and dose-finding clinical trial in Australia. This study specifically targets patients with solid tumors that have stopped responding to anti-PD-1 immunotherapy (like Pembrolizumab or Nivolumab).

• Cohort 1 Status: Completed treatment in all three participants in the first half of 2025, with no device-related serious adverse events reported.
• Cohort 2 Status: Recruitment is underway as of November 2025 under an amended protocol that allows for combination therapy with the anti-PD-1 agents.
• Preliminary Data: Initial data from Cohort 1 showed decreases in large EVs carrying PD-L1 in all three participants after a single 4-hour treatment, a finding associated with improved response to anti-PD-1 agents.

Ongoing Preclinical Collaboration with UCSF for Long COVID Treatment Research

Beyond oncology, the product is being explored for a significant public health crisis: Long COVID. Aethlon Medical has an active preclinical collaboration with the University of California, San Francisco (UCSF) Long COVID Clinic.

The research, which presented data at the Keystone Symposium in August 2025, focuses on the Hemopurifier's ability to bind and remove EVs from Long COVID patient samples. This is a massive market opportunity, as Long COVID is estimated to affect between 44 and 48 million people in the United States alone. The company is currently preparing a manuscript for a peer-reviewed journal based on this collaboration, which could pave the way for future clinical trials in this indication.

Aethlon Medical, Inc. (AEMD) - Marketing Mix: Place

The Place component of Aethlon Medical, Inc.'s strategy is not a traditional commercial distribution network; it is a highly controlled, two-pronged global clinical development pipeline. Since the Hemopurifier is an investigational medical device, the product's availability, or 'Place,' is restricted solely to specific, high-value clinical trial sites and collaborative research institutions in international markets.

Distribution is currently restricted to clinical trial sites in specific international markets

As a clinical-stage company, Aethlon Medical's distribution is a direct-to-institution model, focusing on hospitals and medical centers that can execute complex blood-filtration trials. The Hemopurifier is not available for commercial sale or general physician use. This focused distribution minimizes supply chain complexity but absolutely limits revenue until regulatory approval is achieved, a critical point for investors to understand.

The company's primary focus is on advancing its oncology trial in Australia, which remains better aligned with the goal of generating timely clinical data to support a potential Premarket Approval (PMA) study in the future.

Australian oncology trial is actively recruiting for Cohort 2 under an amended protocol

The Australian oncology trial, a safety, feasibility, and dose-finding study for the Hemopurifier in patients with solid tumors unresponsive to anti-PD-1 agents, is the current anchor of the Place strategy. The trial is conducted across three clinical sites in Australia.

In the first cohort, three participants completed treatment without device deficiencies or immediate complications. Following a positive recommendation from the independent Data Safety Monitoring Board (DSMB) in July 2025, the trial advanced to Cohort 2. The total enrollment for the entire study is projected to be between 9 to 18 participants. Management is targeting a recruitment rate of one patient per month for Cohort 2, which is a key operational metric for this 'Place' of distribution.

Indian regulatory approval was received for a similar oncology study, but trials faced delays

A secondary international 'Place' was established with the receipt of a No Objection Certificate (NOC) from the Indian regulatory authority, the Central Drugs Standard Control Organization (CDSCO), and full ethics approval from the Medanta Institutional Ethics Committee (MIEC) in September 2024. This approval paved the way for a similar oncology trial at Medanta Medicity Hospital in Gurugram, India.

However, the timeline for this distribution channel has been pushed back. As of August 2025, discussions with the India-based Contract Research Organization (CRO) indicated that the first patient treatment would likely not occur until the beginning of 2026. This delay means the Indian market remains a potential, not active, place of distribution for the near-term.

Research is conducted via institutional partnerships, like the UCSF collaboration for Long COVID

Beyond the oncology trials, a crucial part of the 'Place' strategy involves institutional research collaborations, which serve as a proving ground for expanded indications. The company is actively collaborating with the University of California San Francisco Medical Center Long COVID clinic.

This collaboration focuses on evaluating plasma samples from Long COVID participants to assess the Hemopurifier's ability to bind extracellular vesicles (EVs). The pre-clinical data from this work was presented at the Keystone Symposium in August 2025, demonstrating the device's ability to remove 98.5% of platelet-derived EVs in a simulated treatment. This research is defintely a strategic move to build the evidence base for future US-based clinical sites.

The company is headquartered in San Diego, California, managing global research initiatives

Aethlon Medical, Inc. manages its entire global research and clinical 'Place' strategy from its headquarters in San Diego, California. This central US location oversees the logistical and regulatory complexities of the international trials, including the three sites in Australia and the single planned site in India. The company's consolidated operating expenses for the three months ended September 30, 2025, were approximately $1.5 million, a 48% reduction from the prior year, reflecting disciplined management of these global initiatives.

• Oversee 3 Australian clinical sites.
• Manage collaboration with UCSF Long COVID clinic.
• Coordinate regulatory path for India trial start in early 2026.

The entire distribution model is a direct-to-clinic, low-volume, high-control system. Finance: draft 13-week cash view by Friday.

Aethlon Medical, Inc. (AEMD) - Marketing Mix: Promotion

Focus on Investor Relations and Scientific Communication

Aethlon Medical, Inc.'s promotion strategy is not a direct-to-consumer campaign; it's a focused communication effort aimed squarely at the financial and scientific communities. This is crucial because the company's Hemopurifier is an investigational medical device, meaning its success hinges on clinical data, regulatory progress, and investor confidence to fund the long development cycle. They are selling a vision of future therapeutic value, not a current product.

This approach involves a disciplined schedule of investor calls, presentations at industry-specific conferences, and strategic press releases to manage market perception and secure necessary capital. Honestly, in biotech, your investor deck is your most important marketing document.

Regular Investor Conference Calls

The company maintains transparency with the market through routine financial and corporate update conference calls. This is where they defintely map out their strategic progress and financial health for analysts and shareholders. For instance, the Fiscal Second Quarter 2026 Earnings call was held on November 12, 2025, at 4:30 PM EST.

The call revealed key financial metrics for the quarter ended September 30, 2025:

• Cash Balance: Approximately $5.8 million as of September 30, 2025.
• Consolidated Operating Expenses: Approximately $1.5 million for the quarter.
• Expense Reduction: Operating expenses were down by approximately $1.4 million, or a 48% decrease, compared to the same period in 2024.

This level of detail is the core of their investor promotion, signaling financial discipline alongside clinical progress.

Presentations at Industry Events

Aethlon Medical uses key industry and investor conferences to present its clinical and strategic updates, directly engaging with potential investors and partners. These events serve as a platform to translate complex scientific work into investment-grade narratives.

A prime example is the presentation at the Emerging Growth Conference 83 on June 17, 2025, where CEO and CFO Jim Franks provided a strategic overview of the Hemopurifier's development pipeline, covering oncology and Long COVID applications. They also presented at the same conference on February 19, 2025, demonstrating a pattern of consistent outreach.

Dissemination of Clinical Data

Scientific promotion is a major pillar, focusing on peer-reviewed publications and conference presentations to establish credibility. The company actively disseminates clinical data and research findings to validate the Hemopurifier's mechanism of action (MOA), which is the removal of harmful extracellular vesicles (EVs) and viruses from circulation.

For their Long COVID research, the company's collaboration with the UC San Francisco Medical Center culminated in the presentation of preclinical data at the Keystone Symposium in August 2025. Furthermore, a manuscript detailing this Long COVID research is actively in preparation for submission to a peer-reviewed journal, a critical step for scientific validation.

Press Releases Highlighting Clinical Progress

Press releases are used as the primary tool for regulatory disclosure and to broadcast key clinical milestones to the broader financial and medical communities. This keeps the market informed of trial progress, which directly impacts the stock's valuation.

Recent press releases have focused on the Australian oncology trial of the Hemopurifier, which is a safety, feasibility, and dose-finding study designed to enroll approximately 9 to 18 participants:

• July 15, 2025: Announced a positive review from the independent Data Safety Monitoring Board (DSMB), recommending advancement to the second clinical trial cohort.
• August 13, 2025: Confirmed the first cohort of three patients in the Australian trial was complete, with no device-related serious adverse events and no dose-limiting toxicities observed.
• October 7, 2025: Highlighted that the Hemopurifier showed changes in Extracellular Vesicles, Extracellular MicroRNAs, and T Cell Numbers in the Australian Oncology Clinical Trial, providing early evidence of biological effect.

The company also announced the issuance of a U.S. Patent (No. 12,409,260) on September 3, 2025, directed to the treatment of Long COVID, which expands their intellectual property (IP) and provides a strong promotional talking point for future applications.

Aethlon Medical, Inc. (AEMD) - Marketing Mix: Price

For a clinical-stage medical device company like Aethlon Medical, Inc., the traditional concept of product price is irrelevant today. The real price action is in the capital markets, focusing on the cost of equity and disciplined internal cost control to extend the cash runway. In this context, the price of Aethlon Medical, Inc. is the price of its stock, which dictates its ability to fund critical clinical trials and research.

No commercial product price exists; the focus is on capital-raising (equity price) and cost control.

You need to look at Aethlon Medical, Inc.'s financial structure, not a sticker price for a medical device. Since the Hemopurifier is still in clinical development for oncology and infectious diseases, there is no commercial revenue stream or product price to analyze. The company's primary financial strategy is capital preservation and raising funds through equity offerings to finance its operations and clinical trials.

A key capital event in late 2025 was the September public offering. The company announced the pricing of an offering of 5,000,000 shares of common stock (or pre-funded warrants) and warrants to purchase up to 5,000,000 shares of common stock. The combined public offering price was set at $0.90 per unit.

Here's the quick math: the gross proceeds from this September 2025 public offering were approximately $4.5 million. What this estimate hides is the net impact; after deducting placement agent fees and other expenses, the net proceeds were approximately $3.9 million, which is the actual cash injection for general corporate purposes, including clinical trial expenses and research.

Consolidated operating expenses for Q2 2026 (ended September 30, 2025) were approximately $1.5 million.

The company's focus on cost control is defintely a core component of its financial price strategy, as it directly impacts how long the existing capital can sustain operations. For the second fiscal quarter of 2026, which ended on September 30, 2025, Aethlon Medical, Inc. reported consolidated operating expenses of approximately $1.5 million. This shows a strong, deliberate effort to manage cash burn.

Operating expenses were reduced by 48% in Q2 2026 compared to the prior-year period, reflecting disciplined cost management.

This operational efficiency is a massive win for investors, as it buys the company more time to hit its clinical milestones. The operating expenses of $1.5 million for Q2 2026 represent a substantial reduction of approximately 48% compared to the $2.9 million reported in the same quarter of the prior fiscal year (Q2 2025). This reduction was driven by several targeted cuts:

• Payroll and related expenses decreased by approximately $778,000, reflecting a lower headcount and reduced bonus accruals.
• General and Administrative expenses declined by approximately $437,000, partly due to lower clinical trial costs and a $218,000 R&D tax incentive.
• Professional fees decreased by approximately $177,000, primarily from reduced investor relations and contract labor expenses.

Cash balance was approximately $5.8 million as of September 30, 2025.

The cash balance is the lifeline for a pre-revenue biotech, and this figure is crucial for assessing the company's near-term viability. As of September 30, 2025, the cash balance stood at approximately $5.8 million. This figure reflects the impact of the September public offering combined with the aggressive cost-cutting measures.

The operating loss for the fiscal year ended March 31, 2025, was approximately $9.3 million.

The operating loss provides the context for the cost-saving urgency. For the full fiscal year ended March 31, 2025, the operating loss was approximately $9.3 million. This is an improvement from the prior year's loss of $12.6 million, but it still underscores the necessity of the recent capital raise and the ongoing cost discipline to manage the burn rate.

The table below summarizes the critical financial metrics that define Aethlon Medical, Inc.'s price and capital strategy as of late 2025: